货号价格

BAF-HM201-100μg / 询价

BAF-HM201-500μg / 询价

BAF-HM201-500μgx2 / 询价

Human BAFFR/TNFRSF13C Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Human BAFFR/TNFRSF13C Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Ser7-Ala71.[Accession | Q96RJ3-1]

分子量大小(Molecular Weight)

The protein has a predicted MW of 33.3 kDa. Due to glycosylation, the protein migrates to 40-48 kDa based on Tris-Bis PAGE result.

内毒素(Endotoxin)

Less than 1EU per μg by the LAL method.

纯度(Purity)

> 95% as determined by Tris-Bis PAGE

制剂(Formulation)

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Tris-Bis PAGE

Human BAFFR on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

ELISA Data

Immobilized Human BAFF Trimer, His Tag at 2μg/ml (100μl/well). Dose response curve for Human BAFFR, hFc Tag with the EC50 of 56.9ng/ml determined by ELISA.

背景(Background)

BAFF binds to three TNF receptor superfamily members: B-cell maturation antigen (BCMA/TNFRSF17), transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI/TNFRSF13B) and BAFF receptor (BAFF R/BR3/TNFRSF13C). These receptors are type III transmembrane proteins that lack a signal peptide. Whereas TACI and BCMA bind BAFF and another TNF superfamily ligand, APRIL (a proliferation-inducing ligand), BAFF R selectively binds BAFF.

分子别名(Synonyms)

CD268; BAFFR; BR3; TNFRSF13C; BROMIX; CVID4; prolixin

文献(References)

(1)Tin K , Peng C , Christopher T , et al. BAFF Receptor mAb Treatment Ameliorates Development and Progression of Atherosclerosis in Hyperlipidemic ApoE?/? Mice[J]. PLoS ONE, 2013, 8(4):e60430-.